Fourteen genes whose altered expression can be used to differentiate normal plasma cells (PC) from multiple myeloma (MM).
| Gene . | Gene function . |
|---|---|
| CD24 | Modulation of B-cell activation responses |
| CD163 | Integral membrane protein and scavenger receptor cysteine-rich (SRCR) superfamily member; thought to play important role in regulating inflammatory response |
| ITGB2 | Cell surface adhesion glycoprotein that can interact with ICAM-1; expressed on tumor cells of low- and medium-grade malignant lymphomas, but characteristically absent on cells of high-grade malignant B cell lymphomas;35,36 absence results in escape from immunosurveillance in lymphoma37 |
| PF4V1 | CXC chemokine |
| PGYL | Allosteric enzyme in carbohydrate metabolism |
| PLA2G7 | Modulates the action of platelet-activating factor (PAF); PAF is a mediator of signaling, activation of proinflammatory cells, alteration of vascular permeability, and stimulation of glycogen metabolism38 |
| ABL1 | Cytoplasmic and nuclear protein tyrosine kinase; activated by certain DNA-damaging agents and involved in a mismatch repair-dependent apoptotic pathway39 |
| GMPS | De novo synthesis of guanine nucleotides |
| H2BHF | Replication-dependent histone |
| ILF3 | M-phase phosphoprotein that heterodimerizes with NF45 to form the NFAT DNA-binding complex; overexpressed in nasopharyngeal carcinoma cells40 |
| MTA1 | Subunit of NURD (nucleosome remodeling and histone deacetylation) complex |
| MVP | Implicated in multidrug resistance; confers a poor prognosis in MM41 |
| PTPRK | Regulates processes involving cell contact and adhesion; forms complexes with beta-catenin and gamma-catenin/plakoglobin |
| QSCN6 | Expressed at higher levels in quiescent cells than in logarithmically growing cells42 |
| Gene . | Gene function . |
|---|---|
| CD24 | Modulation of B-cell activation responses |
| CD163 | Integral membrane protein and scavenger receptor cysteine-rich (SRCR) superfamily member; thought to play important role in regulating inflammatory response |
| ITGB2 | Cell surface adhesion glycoprotein that can interact with ICAM-1; expressed on tumor cells of low- and medium-grade malignant lymphomas, but characteristically absent on cells of high-grade malignant B cell lymphomas;35,36 absence results in escape from immunosurveillance in lymphoma37 |
| PF4V1 | CXC chemokine |
| PGYL | Allosteric enzyme in carbohydrate metabolism |
| PLA2G7 | Modulates the action of platelet-activating factor (PAF); PAF is a mediator of signaling, activation of proinflammatory cells, alteration of vascular permeability, and stimulation of glycogen metabolism38 |
| ABL1 | Cytoplasmic and nuclear protein tyrosine kinase; activated by certain DNA-damaging agents and involved in a mismatch repair-dependent apoptotic pathway39 |
| GMPS | De novo synthesis of guanine nucleotides |
| H2BHF | Replication-dependent histone |
| ILF3 | M-phase phosphoprotein that heterodimerizes with NF45 to form the NFAT DNA-binding complex; overexpressed in nasopharyngeal carcinoma cells40 |
| MTA1 | Subunit of NURD (nucleosome remodeling and histone deacetylation) complex |
| MVP | Implicated in multidrug resistance; confers a poor prognosis in MM41 |
| PTPRK | Regulates processes involving cell contact and adhesion; forms complexes with beta-catenin and gamma-catenin/plakoglobin |
| QSCN6 | Expressed at higher levels in quiescent cells than in logarithmically growing cells42 |